Biotech-Focused Fund Adds Million: Immunome Bet Surges
A leading biotech-focused fund just boosted its Immunome position by a material amount as the stock surged. This arti...
Strengths include clarity and control, while weaknesses may involve complexity and time to maintain across life changes.
28,655 articlesA leading biotech-focused fund just boosted its Immunome position by a material amount as the stock surged. This arti...
Investors are watching canopy growth's medical marijuana as a potential engine for a rebound. This guide breaks down ...
Gold Exposure through the SPDR Gold ETF can anchor a diversified portfolio. This article explains why SPDR Gold Been ...
A stock delivering a 7% dividend yield and yet slipping 20% year-to-date may seem puzzling. This guide explains how t...
A focused look at a $7 million wager on a CNS drug maker in Phase 3. Learn what this move signals about biotech momen...
Centene's Sarah London, the youngest-ever female Fortune 500 CEO, is steering a bold reinvention of the nation's larg...
If you’re weighing AI investing options, two popular ETFs—CHAT and XLK—show two very different paths. This guide brea...
A civil social-media debate this spring highlighted a looming fight over who will own payments: Visa or on-chain stab...
Investors buzzed as metals company stock rocketed higher on regulatory progress and strong demand signals for battery...
SpaceX’s spending mix is shifting. AI takes a bigger slice of the budget than rockets, raising questions for investor...
When a stock pulls back from its highs, investors want to know if the drop is a buying signal or a warning. This guid...
Circle Internet Group stock took a sharp drop as headlines pointed to potential US regulation that could curb stablec...